On Wednesday, the US Food and Drug Administration (FDA) issued a voluntary recall of 135 batches of potassium chloride extended-release capsules due to faulty medication that could potentially cause cardiac arrest. The recall included 114 batches of potassium chloride extended-release capsules manufactured by Glenmark Pharmaceuticals and 21 batches of the same capsules produced by BluePoint Laboratories, on behalf of American Health Packaging.
The FDA stated that the drug recalls were prompted by the failure of the capsules to dissolve properly, which could lead to high potassium levels or hyperkalemia. This condition is associated with an irregular heartbeat that could result in cardiac arrest if left untreated. The FDA advised consumers who have these capsules to stop using them immediately and consult their healthcare providers before resuming any medication.
Glenmark’s recall was issued on Monday, followed by BluePoint’s recall on Tuesday. While no reports of serious adverse events related to the recall have been reported so far, there are concerns about potential side effects such as muscle weakness, shortness of breath, and chest pain associated with hyperkalemia. The FDA has listed the recalled batch numbers for both Glenmark and BluePoint capsules on its website to help consumers identify which products may be affected. Consumers should dispose of any unused or expired medications properly and seek medical attention if they experience any symptoms related to hyperkalemia or other drug side effects.
In conclusion, while these recalls were voluntary, they serve as a reminder of the importance of monitoring medication safety and following proper dosage instructions to avoid potential risks associated with faulty medication. Consumers should always consult their healthcare providers before starting any new medication or making changes to their existing treatment plans.
